Corrects share movement to 41%, not 412%, in first bullet

** Shares of contract research organization Medpace MEDP.O rise 41% to $440.02 in extended trading

** Co forecasts 2025 sales to be between $2.42 billion and $2.52 billion, up from prior range of $2.14 billion to $2.24 billion

** Analysts were expecting 2025 sales to be $2.19 billion — LSEG data

** Co posts Q2 sales of $603.3 million, above est of $538.8 million

** Co reports Q2 net income of $90.3 million, compared to $88.4 million a year ago

** Co also forecasts 2025 non-adjusted earnings per share in the range of $13.76 to $14.53

** Stock down 7% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com))